ARTL

Artelo is a pre-revenue, clinical-stage biopharma whose survival — not its valuation — is the operative question. The 10-K states outright that its financial condition 'raises substantial doubt as to our ability to continue as a going concern': at year-end 2025 the company held ~$0.6M in cash and restricted cash against negative working capital of $3.3M, a $12.9M net loss, and $8.5M of cash used in operations. Do the arithmetic on the provided figures and cash covers roughly a single month of operating burn. That is a company that must raise money imminently or wind down, and it has no revenue in any year shown (FY2021–FY2025) to fall back on.

The balance sheet is already underwater: total assets of $2.80M (down 40.4% YoY) are exceeded by $4.07M of liabilities (up 121.2%), leaving stockholders' equity of -$1.27M and a liabilities/equity ratio of -3.20x. Current liabilities ($4.04M) dwarf current assets ($695K). Losses are widening, not narrowing — net loss deepened from $9.83M in FY2024 to $12.9M in FY2025 (-31.1% YoY) — and accumulated deficit sits at $63.0M. The $-12.52 diluted EPS on just 2.12M shares reflects a reverse split (share count fell 35.2%), a classic maneuver to hold a Nasdaq listing the filing explicitly flags as at risk. Any financing from this position implies severe dilution; management concedes stockholders 'may experience immediate dilution' and that share sales 'may have a depressive effect' on the price.